Every Form 4 that Tyra Biosciences, Inc. (TYRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TYRA filings page.
Tyra Biosciences, Inc. reported a Form 4 showing a grant of stock options to non-employee director Jake Simson, held for the benefit of RA Capital-managed entities. The award covers 13,160 options for common stock at an exercise price of $32.68 per share and was received for no cash cost.
The options were granted under the company’s Non-Employee Director Compensation Program. One-twelfth of the award vests monthly after May 28, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within a year, subject to Mr. Simson’s continued service.
Under Mr. Simson’s arrangement with RA Capital Management, any net cash or stock from exercising these options must be turned over to the adviser for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund, and a separately managed account, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Tyra Biosciences director Rehan Verjee received a stock option grant covering 13,160 shares of common stock, with an exercise price of $32.68 per share. The option was granted under the Non-Employee Director Compensation Program and vests in 12 equal monthly installments after May 28, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within a year and service continues. Following this award, Verjee holds options for 13,160 shares.
Tyra Biosciences director Susan Moran received a grant of stock options covering 13,160 shares of common stock. The options have an exercise price of $32.68 per share and were granted under the company’s Non-Employee Director Compensation Program as equity compensation.
The options vest over time: 1/12 of the 13,160 shares vest monthly after the May 28, 2026 grant date. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested options vest at that meeting, provided she continues serving the company. Following this grant, she holds 13,160 options directly.
Tyra Biosciences, Inc. reported a Form 4 showing a stock option grant covering 13,160 shares of Common Stock to director Jake Simson under the company’s Non-Employee Director Compensation Program. The option has an exercise price of $32.68 per share and expires on May 27, 2036. One-twelfth of the option vests monthly after the May 28, 2026 grant date, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within the first year, subject to continued service. Under Simson’s arrangement with RA Capital Management, L.P., the option is held for the benefit of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., and a separately managed account, and any net cash or stock from exercise must be turned over to RA Capital, so Simson disclaims beneficial ownership of the option and the underlying shares.
Tyra Biosciences director Adele M. Gulfo received a stock option grant for 13,160 shares of common stock at an exercise price of $32.68 per share. This award was issued under the company’s Non-Employee Director Compensation Program and represents compensation rather than an open-market purchase.
The option vests over time: one-twelfth of the shares vest monthly after the May 28, 2026 grant date. If the next annual shareholder meeting occurs before the first anniversary of the grant, any remaining unvested portion will vest on that meeting date, provided she continues serving the company through each vesting date.
Tyra Biosciences director Robert J. More received a grant of stock options covering 13,160 shares of common stock at an exercise price of $32.68 per share. The options expire on May 27, 2036 and vest in 12 equal monthly installments after May 28, 2026. Any remaining unvested portion will fully vest at the next annual stockholder meeting if it occurs before the first anniversary of the grant date, subject to his continuous service.
Tyra Biosciences director Stephen Michael Rothenberg received a new stock option grant covering 13,160 shares of common stock. The options have an exercise price of $32.68 per share and expire on May 27, 2036. The grant was made under the company’s Non-Employee Director Compensation Program.
Vesting is structured so that 1/12 of the option vests monthly after the May 28, 2026 grant date. If the next annual stockholder meeting occurs before the first anniversary of grant, any remaining unvested portion vests on that meeting date, subject to continued service.
Tyra Biosciences, Inc. reported that Chief Medical Officer Douglas J. Warner received new equity awards as part of his compensation. He was granted 25,000 restricted stock units (RSUs), each representing one share of common stock, with one quarter vesting on each of the first four anniversaries of May 5, 2026, subject to his continuous service. He also received a stock option for 85,000 shares of common stock at an exercise price of $33.93 per share, vesting in equal monthly installments over 48 months following May 5, 2026, also conditioned on continued service. These are grants and not open‑market purchases or sales.
Tyra Biosciences, Inc. granted Chief Financial Officer Alan Fuhrman new equity awards on May 5, 2026. He received 20,000 restricted stock units, which vest in four equal annual installments starting on May 5, 2027, each RSU representing one share of common stock. He was also granted options on 67,000 shares of common stock at an exercise price of $33.93 per share, vesting monthly over four years and expiring on May 4, 2036. Following these awards, he directly owns 36,164 shares of common stock, including RSUs.
Tyra Biosciences President and CEO Harris Todd received new equity awards that increase his long-term stake in the company. He was granted 79,000 restricted stock units on May 5, 2026, bringing his direct common stock holdings to 1,437,631 shares after the award.
He also received a stock option for 265,000 shares of common stock at an exercise price of $33.93 per share, expiring on May 4, 2036. The RSUs vest in four equal annual installments starting on the first anniversary of May 5, 2026, while the option vests monthly over 48 months from the same date, in each case subject to his continuous service.
Tyra Biosciences Chief Operating Officer Ashar Bhavesh received new equity awards in the form of restricted stock units and stock options. On May 5, 2026, Bhavesh was granted 15,013 RSUs, each representing a right to receive one share of common stock, and 50,295 stock options with an exercise price of $33.93 per share.
According to the vesting terms, one quarter of the RSUs vests on each of the first four anniversaries of May 5, 2026, subject to continued service. For the options, 25% of the shares vest on May 5, 2027 and the remainder vests in equal monthly installments over the following three years, with the options expiring on May 4, 2036.
Tyra Biosciences, Inc. reported that Vice President, Finance (PAO) Yuliya Rueb received equity compensation on May 5, 2026. She was granted 8,333 restricted stock units (RSUs), each representing one share of common stock, with 1/4 of the RSUs vesting on each of the first four anniversaries of May 5, 2026, subject to continued service. Following this grant, she holds 43,354 shares of common stock directly, including RSUs. She was also granted a stock option for 28,000 shares of common stock at an exercise price of $33.93 per share, expiring on May 4, 2036, with 1/48 of the option shares vesting monthly after May 5, 2026, as long as she remains in service.
Tyra Biosciences director Habib J. Dable received a grant of stock options covering 44,400 shares of common stock at an exercise price of $35.12 per share. The options expire on April 15, 2036 and vest monthly in 36 equal installments starting after April 16, 2026, contingent on continued service.
Tyra Biosciences director Gilla Kaplan reported option exercises and related share dispositions. Kaplan exercised stock options to acquire a total of 67,467 shares of common stock at an exercise price of $2.25 per share on March 25–26, 2026.
On March 25, 2026, Kaplan acquired 14,295 shares via option exercise and sold 14,295 shares of common stock in open-market transactions at a weighted average price of $36.9714 per share, with individual sale prices ranging from $36.95 to $37.11. On March 26, 2026, Kaplan exercised options for 53,172 shares and disposed of 53,172 shares back to the issuer at $37.7483 per share.
Following these transactions, Kaplan directly owned 28,231 shares of Tyra Biosciences common stock. The exercised options were reported as fully vested, and there are no remaining derivative positions shown in this filing.
Tyra Biosciences, Inc. Chief Financial Officer Alan Fuhrman increased his holdings through the company’s employee stock purchase plan. On March 13, 2026, he acquired 1,376 shares of common stock at $9.129 per share under the 2021 Employee Stock Purchase Plan. After this ESPP acquisition, he directly owns 16,164 common shares, reflecting a routine, compensation-related increase rather than an open-market purchase.
Tyra Biosciences President and CEO Harris Todd increased his direct holdings through a compensation-related share acquisition. On March 13, 2026, he acquired 1,463 shares of Tyra Biosciences common stock at $9.129 per share under the company’s 2021 Employee Stock Purchase Plan.
After this transaction, Todd directly owns 1,358,631 common shares. This was a grant/award-type acquisition under an employee plan, not an open-market purchase, and represents a small addition relative to his existing stake.
Tyra Biosciences, Inc. Chief Discovery Officer Daniel Bensen reported planned stock sales. On February 12, 2026, he completed two open-market sales of Tyra Biosciences common stock under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024.
Bensen sold 2,128 shares at a weighted average price of $31.5018, with actual prices ranging from $31.02 to $31.75, and 5,872 shares at a weighted average price of $33.3666, with actual prices between $32.98 and $33.85. Following these transactions, he directly owned 146,981 shares of Tyra Biosciences common stock.
Tyra Biosciences Chief Discovery Officer Bensen Daniel reported preset insider stock sales. On January 12, 2026, he sold 6,983 shares of Tyra Biosciences common stock at a weighted average price of $28.442 and an additional 1,017 shares at a weighted average price of $29.0808, both listed as open-market sales. These trades were carried out under a Rule 10b5-1 trading plan adopted on November 5, 2024, which is designed to pre-schedule transactions. After these sales, Daniel beneficially owned 154,981 shares of Tyra Biosciences common stock in direct ownership.
Tyra Biosciences, Inc. reported that an officer serving as Chief Discovery Officer sold 8,000 shares of common stock on 12/12/2025. The transaction was coded as a sale and executed at a weighted average price of $22.6449, with individual sale prices ranging from $22.06 to $23.03.
The filing states that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024. Following this transaction, the officer beneficially owns 162,981 shares of Tyra Biosciences common stock, held directly.
Tyra Biosciences, Inc. (TYRA) reported an insider transaction by a director associated with Alta Partners NextGen Fund II, L.P. On 11/21/2025, the fund sold 246,871 shares of common stock in an open-market transaction coded as a sale. The shares were sold under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2025.
The filing states a weighted average sale price of $20.2536 per share, with individual sale prices ranging from $20.25 to $21.24. After this transaction, 3,833,425 shares of Tyra Biosciences common stock are reported as beneficially owned indirectly through the fund. The reporting person notes that beneficial ownership is disclaimed beyond his pecuniary interest in those shares.
Tyra Biosciences, Inc. reported insider stock sales by its Chief Operating Officer. The executive filed a Form 4 showing open-market sales of Tyra common stock on 11/18/2025 and 11/19/2025. On the first date, the officer sold 75,633 shares of common stock at a weighted average price of $16.0727, leaving 220,937 shares beneficially owned directly afterward. On the second date, the officer sold an additional 49,956 shares at a weighted average price of $16.3203, and reported direct beneficial ownership of 170,981 shares following that transaction. The filing notes that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, which is designed to allow insiders to sell shares according to a preset schedule.
Tyra Biosciences, Inc. Chief Operating Officer, listed as an officer and sole reporting person, reported multiple open-market sales of common stock. On 11/13/2025, the COO sold 1,111 shares at a weighted average price of $16.0036, leaving 426,870 shares beneficially owned. On 11/14/2025, an additional 110,228 shares were sold at a weighted average price of $16.0167, reducing beneficial ownership to 316,642 shares. On 11/17/2025, the COO reported sales of 18,572 shares at a weighted average price of $16.1098 and 1,500 shares at a weighted average price of $17.0713, resulting in 296,570 shares of common stock beneficially owned following the transactions.
The filing states that all reported sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, and that the disclosed prices represent weighted averages over multiple trades within specified price ranges.
Tyra Biosciences insider purchase under ESPP: The company's Chief Financial Officer, Alan Fuhrman, acquired 701 shares of Tyra Biosciences common stock on 09/15/2025 at a purchase price of $9.129 per share under the issuer's 2021 Employee Stock Purchase Plan. After the transaction, Mr. Fuhrman beneficially owned 14,788 shares. The Form 4 was signed by an attorney-in-fact on 09/17/2025.